| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
44,351 | 29,823 | 16,302 | 13,175 | 7,574 | 3,707 | 1,541 |
Acquired in-process research and development | ||||||
6,567 | - | - | - | - | - | - |
General and administrative | ||||||
12,154 | 9,876 | 6,185 | 5,520 | 4,414 | 3,563 | 2,134 |
Loss from operations | ||||||
-63,074 | -39,699 | -22,488 | -18,695 | -11,989 | -7,270 | -3,676 |
Other income (expense): | ||||||
Change in fair value of preferred stock warrant liabilities | ||||||
- | - | - | - | - | -2,327 | -720 |
Change in fair value of convertible preferred stock rights and rights option liabilities | ||||||
- | - | - | - | - | - | 16,175 |
Interest income | ||||||
1,541 | 952 | 261 | 102 | 11 | 0 | 0 |
Interest expense | ||||||
603 | 146 | 113 | 105 | 112 | 244 | 159 |
Total other income (expense), net | ||||||
937 | 805 | 147 | -3 | -101 | 2,083 | 16,736 |
Loss before income taxes | ||||||
-62,136 | -38,893 | - | - | - | - | - |
Income tax benefit | ||||||
-1,309 | - | - | - | - | - | - |
Net loss | ||||||
-60,826 | -38,893 | -22,340 | -18,699 | -12,090 | -5,187 | 13,060 |
Net loss per share - basic and diluted | ||||||
-2.24 | -1.79 | -1.40 | -1.65 | -1.40 | - | - |
Weighted average common shares outstanding - basic and diluted | ||||||
27,111 | 21,685 | 15,921 | 11,352 | 8,633 | - | - |
Accretion of preferred stock | ||||||
- | - | - | - | - | 333 | 822 |
Deemed dividend | ||||||
- | - | - | - | - | 4,053 | - |
Allocation of undistributed earnings to preferred stockholders | ||||||
- | - | - | - | - | - | 11,128 |
Net loss attributable to common stockholders | ||||||
- | - | - | - | - | -9,573 | 1,109 |
Basic | ||||||
- | - | - | - | - | -2.51 | 3.49 |
Diluted | ||||||
- | - | - | - | - | -3.09 | -17.61 |
Basic | ||||||
- | - | - | - | - | 3,818 | 318 |
Diluted | ||||||
- | - | - | - | - | 3,850 | 855 |